Author(s):
Ruchira Sanjay Chandane, Sanika Rajaram Charane, Tanaya Ulhas Vanjale, Swapnil Ingavale, Dhanraj Jadge, Mahesh Kolap
Email(s):
kolapmb@gmail.com
DOI:
10.52711/2321-5836.2026.00032 
Address:
Ruchira Sanjay Chandane, Sanika Rajaram Charane, Tanaya Ulhas Vanjale, Swapnil Ingavale, Dhanraj Jadge, Mahesh Kolap
Womens College of Pharmacy, Peth Vadgaon, Kolhapur, 416112, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Recent antimalarial drug discovery has been a race to produce new medicines that overcome emerging drug resistance, whilst considering safety and improving dosing convenience. Discovery efforts have yielded a variety of new molecules, many with novel modes of action, and the most advanced are in late-stage clinical development. These discoveries have led to a deeper understanding of how antimalarial drugs act, the identification of a new generation of drug targets, and multiple structure-based chemistry initiatives. The limited pool of funding means it is vital to prioritize new drug candidates. They should exhibit high potency, a low propensity for resistance, a pharmacokinetic profile that favours infrequent dosing, low cost, preclinical results that demonstrate safety and tolerability in women and infants, and preferably the ability to block Plasmodium transmission to Anopheles mosquito vectors. In this Review, we describe the approaches that have been successful, progress in preclinical and clinical development, and existing challenges. We illustrate how antimalarial drug discovery can serve as a model for drug discovery in diseases of poverty.
Cite this article:
Ruchira Sanjay Chandane, Sanika Rajaram Charane, Tanaya Ulhas Vanjale, Swapnil Ingavale, Dhanraj Jadge, Mahesh Kolap. Review on Malaria. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):238-6. doi: 10.52711/2321-5836.2026.00032
Cite(Electronic):
Ruchira Sanjay Chandane, Sanika Rajaram Charane, Tanaya Ulhas Vanjale, Swapnil Ingavale, Dhanraj Jadge, Mahesh Kolap. Review on Malaria. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):238-6. doi: 10.52711/2321-5836.2026.00032 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-3-3
REFERENCES:
1. L Siqueira-Neto et al. Nat Rev Drug Discov. 2023 Oct.
2. Int J Antimicrob Agents. 2013 Feb 8.
3. Basu S. Sahi PK. Malaria: An update. The Indian J Pediat 2017; 84(7): 5219.
4. Nadjim B. Beherens RH. Malaria: An Update for physicians. Infect Dis Clin. 2012; 26(2): 243-59
5. Walter K, John CC. Malaria. JAMA. 2022; 327(6): 597 doi:10.1001/jama.2021.21468
6. DIO10.13140/RG.2.1.1325.6802/1December 2012
7. Dipiro JT. Handbook of Pharmacotherapy. 7th ed. and others, editor: 1998. p. 132-40
8. Schofield L. Hackett F. Signal transduction in host ceils by a glycophosphatidylinositol toxin of malaria parasites. J Exp Med. 1993; 177(1): 145-53.
9. Clark IA, Cowden WB. The pathophysiology of Falciparum malaria.Pharma Ther. 2003; 99(2): 221-60.
10. Perkins DJ, Were T. Davenport GC, Kempaiah P. Hittner JB, Ong'echa JM. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci. 2011; 7(9): 1627-9.
11. Claire L. Mackintosh, James G. Beeson, Kevin Marsh. Clinical features and pathogenesis of severe malaria. Trends in Parasitology December 2004; 20(12): 597-603
12. DIO10.13140/RG.2.1.1325.6802/1December 2012
13. Gitau GM, Eldrd JM. Malaria in pregnancy: clinical, therapeutic and prophylactic considerations. Obstetrician Gynecologist. 2005; 7(1): 5
14. World Health Organization. Severe falciparum malaria. Transactions of Royal Society of Tropical Medicine and Hygiene. Trans R SocTrop Med Hyg. 2000; 94: 1–90.
15. Chauhan V, Negi RC, Verma B, Thakur S. Transfusion transmitted malaria in a Non-endemic area. J Association Phys India. 2009; 57: 653–7.
16. Slinger R, Giulivi A, Bodie-Collins M, Hindieh F, John RS, Sher
17. G, et al. Transfusion-transmitted malaria in Canada. Canada.2001; 164(3): 377–86.
18. Bruce C. Transfusion malaria revisited. Trop Dis Bull. 1982; 79(10): 827–67.
19. Transfusion malaria: Serologic Identification of Infected Donors Pennsylvania, Georgia, MMWR.Morbidity and mortality weekly report. Centers Dis Control. 1983; 32(17): 222–31.
20. Seed CR, Kitchen A, Davis TM. The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev. 2005; 19(3): 229–69.
21. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox sanguinis. 1990; 90(2): 77–84.
22. Owusu-Ofori AK, Parry C, Bates I. Transfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis. 2010; 51(10): 1192–200.
23. Allain JP. Malaria and transfusion: a neglected subject coming back to the forefront. Clin infect Dis. 2010; 51(10): 1199–200.
24. Bahadur S, Pujani M, Jain M. Use of rapid detection tests to prevent transfusion- transmitted malaria in India. Asian J Transfus Sci. 2010; 4(2): 140–1.
25. June 2024 Amal A El-Moamly
26. McCutchan, Thomas F.; Piper. Robert C.; Makler, Michael T. (November 2008). "Use of Malaria Rapid Diagnostic Test to Identify Plasmodium knowlesi Infection". Emerging Infectious Disease (Centers for Disease Control) 14(11): 1750-2
27. Molecular Diagnosis & Therapy · September 2012
28. 31. Mens PF, Schoone GJ, Kager PA. Advances and roadblocks in the treatment of malaria. Brit J Clin Pharmacol. 2006; 88(2): 374-82.
29. Merrifield R, Penofold HA, Reid SD, Smith PC, Stevens MM, Templeton MR, et al. Technologies for global health. Lancet. 2012; 380(9840): 507-42.
30. Pousibet-Puerto J, Salas-Coronas J, Sanchez-Crespo A, Molina- Arrebola MA, Soriano-Perez MJ, Lopez G, et al. Impact of using artemisinin-based combination therapy (ACT) in treatment of uncomplicated malaria from Plasmodium falciparum in a non- endemic zone. Malaria journal. 2016; 15(1): 339-339.
31. McIntosh H. Chloroquine or Amodiaquine combined with Sulfadoxine- pyrimethamine for treating uncomplicated malaria. The Cochrane Datab Sys Rev. 2005; 4: CD000386.
32. Keating GM. Dihyroartemisinin/piperaquine: A review of its use in the treatment of uncomplicated Plasmodium falciparum malaria Drugs. Drugs. 2012; 72(7): 937-61.
33. Amukoye E. Winstaley PA, Watkins WM, Snow RW, Hatcher J, Mosobo M. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2017; 41(10): 2264. doi:10.1128/aac.41.10.2261.
34. Tarning J. Treatment of Malaria in Pregnancy. New Engl J Med. 2018; 374(10): 981-2.
35. Manyando C. Kayentao K, 'alessandro D. Okarfor U, Juma HU, Hamed E. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malaria J. 2011; 11: 141. doi:10.1186/1475-2875-11-141.
36. Kochar DK, Saxena V, Singh N. Kochar SK, Kumar V, Das S, et al. lasmodium vivax Malaria. Emerg Infect Dis. 2005; 11(1): 132-6.
37. Pasvol G. Treatment of complicated and severe malaria. Malaria.2005: 75: 29-49.
38. CDC- Centers for Disease Control. CDC-Malaria-Diagnosis and Treatment (United States) -Treatment. Available from: https://www.cdc.gov/malaria/ diagnosis_treatment/clinicians 1.html#: text=Severe%20malaria%20can%20progress%20to, with% 20intravenous%20(IV)%20artesunate.
39. Kyu HH, Fernandez E. Artemisinin derivatives versus quinine for cerebral malaria in African children: a systematic review. Bull World Health Organ. 2009; 87(12): 896-904.
40. Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res. 2010; 68(4): 267–74.
41. Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria. Cochrane Datab Syst Rev. 2002; 2: 225.
42. Van Vugt M, Brockman A, Gemperli B, Luxem- burger C, Gathmann I, Royce C, Slight T, Looaree- suwan S, White N J, Nosten F. A randomized com- parison of artemether-benflumetol and artesunate- mefloquine in the treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother.1998; 42: 135–139.